Login to Your Account

Other News To Note

Thursday, April 11, 2013
• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said it will receive a $3.5 million grant from the National Institute of Allergy and Infectious Diseases to advance the development of its next-generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription